Five Prime Therapeutics Announces Addition of Julie Hambleton, M.D., as Senior Vice President and Chief Medical Officer

Five Prime Therapeutics Announces Addition of Julie Hambleton, M.D., as Senior
Vice President and Chief Medical Officer

SOUTH SAN FRANCISCO, Calif., Dec. 3, 2012 (GLOBE NEWSWIRE) -- Five Prime
Therapeutics, Inc. (FivePrime), a clinical-stage company discovering and
developing innovative antibody and protein therapeutics, announced today that
Julie Hambleton, MD, has joined FivePrime as Senior Vice President and Chief
Medical Officer, bringing over 25 years of clinical, academic and drug
development experience to FivePrime.

"Dr. Hambleton is a premier drug developer and leader in the industry and we
are delighted that she has joined FivePrime," said Lewis T. "Rusty" Williams,
MD, PhD, Founder, President and Chief Executive Officer of FivePrime."Dr.
Hambleton's extensive pharmaceutical development track record and the breadth
and depth of her expertise will strengthen our executive team.We expect Dr.
Hambleton will have a significant impact on FivePrime's continued evolution as
a development-stage company."

Prior to joining FivePrime, Dr. Hambleton served as Vice President, Clinical
Development, at Clovis Oncology, Inc. where she oversaw the clinical
development of CO-1686, a mutant selective epidermal growth factor receptor
(EGFR) inhibitor targeting non-small cell lung cancer, and rucaparib, a poly
ADP-ribose polymerase (PARP) inhibitor initially targeting ovarian and breast
cancers.From 2003 to 2010, Dr. Hambleton served at Genentech, Inc. in
positions of increasing responsibility, most recently as Group Medical
Director, Global Clinical Development, leading a cross-functional group
conducting seven phase 3 trials of Genentech's Avastin^® (bevacizumab)
antibody in different indications.

During her tenure at both Clovis and Genentech, Dr. Hambleton played a
significant role in drug development programs for numerous molecules at all
stages of development—from pre-clinical through phase 4 and other
post-marketing studies—involving more than two dozen clinical trials.She also
brings to FivePrime extensive experience working with regulatory agencies to
advance the development of new molecules, including with the U.S. Food and
Drug Administration and the European Medicines Agency (EMA), and has played a
significant role in filings of investigational new drug (IND) applications,
biologics license applications (BLAs) and special protocol assessments (SPAs).

Prior to joining industry, Dr. Hambleton served for 10 years in academic
positions in the Division of Hematology/Oncology at the University of
California, San Francisco (UCSF), most recently as Associate Professor of
Clinical Medicine.Prior to her academic positions, she completed seven years
of post-graduate training at UCSF, where she served as Chief Medical Resident
and a Fellow in the Division of Hematology/Oncology.

Dr. Hambleton received a B.S. degree from Duke University, and an M.D. degree
from Case Western Reserve University School of Medicine. She is
Board-certified in Hematology and Internal Medicine.

About FivePrime

Five Prime Therapeutics, Inc. is a clinical-stage, privately held,
biotechnology company discovering and developing innovative antibody and
protein therapeutics. Using its integrated discovery platform, FivePrime is
building a strong pipeline of oncology and immunology drug candidates.
FivePrime mines its comprehensive library of secreted and extracellular human
proteins to screen for medically relevant new therapeutic proteins and
antibody targets. FivePrime has entered into a collaboration agreement to
develop and commercialize its lead product, FP-1039, with Human Genome
Sciences, Inc. (which GlaxoSmithKline has acquired) in the United States,
Canada and the EU. FivePrime has also established significant collaborations
for the discovery of innovative biologics in specific therapeutic areas with
several leading pharmaceutical companies, including Pfizer, Centocor and
GlaxoSmithKline. For more information about FivePrime, please visit
FivePrime's web site at www.fiveprime.com.

The Five Prime Therapeutics, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=8029

CONTACT: Amy Kendall
         Corporate Communications
         415-365-5776
         amy.kendall@fiveprime.com

Five Prime Therapeutics, Inc. Logo